


## Bromoacetamido-PEG4-acid

<b>Cat. No.:</b>	HY-141382		
<b>CAS No.:</b>	1807518-67-7		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>24</sub> BrNO <sub>7</sub>		
<b>Molecular Weight:</b>	386.24		
<b>Target:</b>	PROTAC Linkers; ADC Linker		
<b>Pathway:</b>	PROTAC; Antibody-drug Conjugate/ADC Related		
<b>Storage:</b>	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	PEGs	Cleavable Linker
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

### REFERENCES

- [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562.
- [2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov*. 2017 May;16(5):315-337.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA